Showing results (1351-1360 of 2,361) with videos related to
Sort By:
Pageof 237
Clinical Neuropharmacology|June 5, 2003
Cholinergic-dopaminergic imbalance in Pisa syndromeAlberto Villarejo, Ana Camacho, Rocío García-Ramos, et al.Clinical Neuropharmacology|June 5, 2003
Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's diseaseFabrizio Stocchi, Alfredo Berardelli, Laura Vacca, et al.Clinical Neuropharmacology|June 5, 2003
Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tabletsDag Nyholm, Håkan Askmark, Cecilia Gomes-Trolin, et al.Clinical Neuropharmacology|June 5, 2003
Effectiveness of Gorei-san (TJ-17) for treatment of SSRI-induced nausea and dyspepsia: preliminary observationsKazuo Yamada, Gohei Yagi, Shigenobu KanbaClinical Neuropharmacology|October 2, 2003
Poor tolerability of a transdermal nicotine treatment in Parkinson's diseaseSimon Lemay, Pierre Blanchet, Sylvain Chouinard, et al.Clinical Neuropharmacology|October 2, 2003
The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementiaMarco Onofrj, Astrid Thomas, Diego Iacono, et al.Clinical Neuropharmacology|October 2, 2003
Suppression of alcohol delirium tremens by baclofen administration: a case reportGiovanni Addolorato, Lorenzo Leggio, Ludovico Abenavoli, et al.Clinical Neuropharmacology|October 2, 2003
Neuroprotective effect of deprenyl in sensory neurons of axotomized dorsal root ganglionRahim Hobbenaghi, Taki TiraihiClinical Neuropharmacology|October 2, 2003
Progressive worsening of adaptive functions in Down syndrome may be mediated by the complexing of soluble Abeta peptides with the alpha 7 nicotinic acetylcholine receptor: therapeutic implicationsStephen I Deutsch, Richard B Rosse, John Mastropaolo, et al.Pageof 237